Abstract:Background: For any drug molecule, it is mandatory to pass the drug approval process of the concerned regulatory authority, before being marketed. The Food and Drug Administration (FDA), throughout the year, approves several new drugs for safety and efficacy. In addition to new drug approvals, FDA also works on improving access to generic drugs, aimed to lower the cost of drugs for patients and improve access to treatments. In the year 2022 twelve new drug therapies were approved for managing varying cancers. Methods: This manuscript is focused to describe the pharmacological aspects including therapeutic uses, mechanisms of actions, pharmacokinetics, adverse effects, doses, indication for special cases, contraindications, etc., of novel FDA-approved anticancer drug therapies in the year 2022. Result: FDA has approved about 29% (11 out of 37) novel drug therapies for varying types of cancers such as lung cancer, breast cancer, prostate cancer, melanoma, leukemia, etc. The Center for Drug Evaluation and Research CDER has reported that 90% of these anticancer drugs (e.g. Adagrasib, Futibatinib, Mirvetuximabsoravtansine-gynx, Mosunetuzumab-axb, Nivolumab and relatlimab-rmbw, Olutasidenib, Pacritinib, Tebentafusp-tebn, Teclistamab-cqyv, and Tremelimumab-actl) as orphan drugs and recommended to treat rare or uncommon cancers such as non-small cell lung cancer, metastatic intrahepatic cholangio-carcinoma, epithelial ovarian cancer, follicular lymphoma, metastatic melanoma, metastatic uveal melanoma, etc. CDER has identified six anticancer drugs (e.g. Lutetium (177Lu)vipivotidetetraxetan, Mirvetuximabsoravtansine-gynx, Mosunetuzumab-axb, Nivolumab and relatlimab-rmbw, Tebentafusp-tebn, Teclistamab-cqyv) as first-in-class drugs i.e. drugs having different mechanisms of action from the already existing ones. The newly approved anticancer drugs shall provide more efficient treatment options for cancer patients. Three FDA-approved anticancer drugs in the year 2023 are also briefly described in the manuscript. Conclusion: This manuscript, describing the pharmacological aspects of eleven anticancer novel drug therapies approved by the FDA, shall serve as a helpful document for cancer patients, concerned academicians, researchers, and clinicians, especially oncologists.

An update of new small-molecule anticancer drugs approved from 2015 to 2020

The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020

An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021)

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Small molecule anticancer drugs approved during 2021-2022: Synthesis and clinical applications

FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I

A systematic analysis of FDA-approved anticancer drugs

Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors As Anticancer Agents

Basic approaches, challenges and opportunities for the discovery of small molecule anti-tumor drugs

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Recent Advances in Small Molecule Prodrugs for Cancer Therapy

Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review

Innovative Drugs Promote Precision Cancer Therapy

Rethinking therapeutic strategies of dual‐target drugs: An update on pharmacological small‐molecule compounds in cancer

Anticancer drugs approved by the U.S.FDA in the past 10 years

Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

Reviewing the Synthesis and Clinical Application of FDA-Approved Anticancer Medications

Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer

Finding New Tricks for Old Drugs: Tumoricidal Activity of Non-Traditional Antitumor Drugs

Small-molecule agents for cancer immunotherapy